The UK is preparing to launch a pioneering AI sandbox designed to explore how artificial intelligence can improve medicine safety and accelerate the development of new treatments.
Led by the Medicines and Healthcare products Regulatory Agency (MHRA), the initiative will create a controlled testing environment where researchers, technology firms and regulators can evaluate emerging AI tools.
The programme, backed by the government’s Regulatory Innovation Office, aims to address long-standing challenges in drug development and patient safety.
By allowing innovators to test AI systems under regulatory oversight, the UK hopes to identify more reliable ways to predict medication-related risks before treatments reach patients.
Officials believe the initiative could help reduce adverse drug reactions, which currently lead to approximately 250,000 hospital admissions across the UK each year and place a financial burden of more than £2bn on the NHS.
The project is also expected to provide stronger evidence on the effectiveness of AI in supporting regulatory decision-making.
UK Health Innovation Minister Preet Gill explained: “The AI revolution is here, and we want our NHS staff to be the first in the queue, armed with rigorously tested clinical AI tools.
“By giving innovators a safe space to test these tools alongside regulators, we can build the evidence base needed to get safer, more effective treatments to patients faster.
“That means fewer adverse reactions, less reliance on animal testing, and a smarter, more efficient medicines development process.”
What will the AI sandbox do?
Developing safe and effective medicines remains a complex and expensive process. Around 90% of drug candidates fail during development, often because existing testing methods cannot accurately predict how treatments will behave in humans.
The new AI sandbox will enable companies and academic researchers to trial advanced technologies capable of modelling how medicines are absorbed, metabolised and processed within the body.
These systems may also identify potential safety concerns earlier than traditional approaches, helping researchers make more informed decisions during development.
By testing these tools in a supervised environment, regulators can better understand their reliability, limitations and potential role in future medicine assessments.
Improving medicine safety for diverse patient groups
A key focus of the programme is improving the use of clinical data to understand how medicines affect different populations.
This includes groups that are frequently underrepresented in medical research, such as children, older adults and people from diverse ethnic backgrounds.
Researchers will examine whether AI can uncover patterns and risks that conventional testing methods may overlook. Greater insight into how treatments perform across varied populations could strengthen medicine safety standards and support more personalised healthcare approaches.
Supporting innovation and regulatory modernisation
The initiative forms part of the UK’s broader strategy to modernise medicine development through advanced technologies, including AI, synthetic data and predictive modelling.
The MHRA intends to use findings from the programme to establish clearer guidance on the safe and responsible use of AI within the pharmaceutical sector.
A stronger regulatory framework could encourage greater investment in UK life sciences and provide companies with increased confidence when developing innovative treatments.
Science Minister Lord Vallance added: “Too many promising medicines fail late in development or never reach patients because the evidence needed to support them is difficult and slow to generate.
“By leveraging our strengths in life sciences, AI and pro-innovation regulation, this sandbox will help make the UK one of the best places in the world to develop the next generation of medicines safely.”
First phase begins in 2026
Up to five AI-powered approaches will be selected for testing during the sandbox’s initial phase.
The MHRA plans to begin collaborating with industry and academic partners from summer 2026 to shape the programme and evaluate potential use cases.
The project also supports the government’s wider ambitions to create one of the world’s most AI-enabled healthcare systems while reducing reliance on animal testing.
If successful, the AI sandbox could play a significant role in advancing medicine safety, accelerating drug discovery and improving patient outcomes across the UK.